Drugs / Octenidinedihydrochlorid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03322124 | Jan → Dec 2018 | — | Schülke & Mayr GmbH | Completed | No outcome recorded |
| Phase 3 | NCT03378401 | Jan → Sep 2018 | — | Schülke & Mayr GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octenidinedihydrochlorid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378401 ↗ |
| Route | Other | “for oromucosal use” NCT03322124 ↗ |